Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 1,416 -0.51%
02 Jun - close price
betadrugslimited.com NSE: BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Market Position
The company is ranked among the top 10 oncology companies, and many of its key products are ranked among the top 5 in their respective categories. [1]

Website NSE
  • Market Cap ₹ 1,435 Cr.
  • Current Price ₹ 1,416
  • High / Low ₹ 2,000 / 990
  • Stock P/E 34.6
  • Book Value ₹ 241
  • Dividend Yield 0.00 %
  • ROCE 19.2 %
  • ROE 18.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2024 Mar 2025 Sep 2025 Dec 2025 Mar 2026
88.29 93.76 103.39 87.27 93.96
69.83 76.41 82.09 70.29 76.28
Operating Profit 18.46 17.35 21.30 16.98 17.68
OPM % 20.91% 18.50% 20.60% 19.46% 18.82%
-1.38 1.74 2.99 2.31 2.89
Interest 1.88 3.29 3.61 4.43 3.94
Depreciation 3.24 3.57 4.24 4.39 4.80
Profit before tax 11.96 12.23 16.44 10.47 11.83
Tax % 25.17% 26.17% 25.73% 18.62% 23.50%
8.95 9.03 12.22 8.52 9.05
EPS in Rs 8.86 8.95 12.11 8.40 8.93
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
51 66 91 116 184 227 296 362 385
41 54 73 91 141 174 236 288 309
Operating Profit 9 12 18 25 43 53 60 75 76
OPM % 19% 18% 20% 21% 23% 23% 20% 21% 20%
0 0 0 0 1 1 1 2 11
Interest 1 1 3 2 2 2 3 7 15
Depreciation 2 3 4 7 7 10 10 13 17
Profit before tax 7 8 12 16 34 41 49 57 54
Tax % 1% -2% 21% 27% 28% 25% 25% 26% 24%
7 8 9 12 25 31 36 42 41
EPS in Rs 7.43 8.84 9.33 11.60 24.58 30.42 36.08 42.02 40.92
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 27%
3 Years: 19%
TTM: 6%
Compounded Profit Growth
10 Years: %
5 Years: 29%
3 Years: 11%
TTM: -9%
Stock Price CAGR
10 Years: %
5 Years: 38%
3 Years: 25%
1 Year: -25%
Return on Equity
10 Years: %
5 Years: 25%
3 Years: 23%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 9 10 10 10 10 10 10 10
Reserves 24 32 48 59 83 113 148 187 235
8 20 23 17 21 20 15 138 148
9 22 28 31 45 55 82 101 103
Total Liabilities 50 83 107 118 158 198 254 436 496
13 18 44 40 55 63 65 89 125
CWIP 1 15 0 3 0 0 0 0 0
Investments 0 0 0 1 1 1 0 0 0
35 50 63 74 102 135 190 347 371
Total Assets 50 83 107 118 158 198 254 436 496

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
17 0 8 19 30 23 31 36 37
-11 -21 -15 -6 -22 -19 -14 -36 -51
5 12 9 -8 -1 -2 -7 118 -8
Net Cash Flow 12 -9 2 5 7 2 9 118 -22
Free Cash Flow 9 -21 -7 13 10 5 19 -1 -16
CFO/OP 181% 1% 47% 75% 69% 44% 52% 48% 49%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 104 139 128 106 90 101 98 103 113
Inventory Days 37 104 102 100 87 106 122 127 159
Days Payable 81 143 119 127 123 139 145 152 172
Cash Conversion Cycle 60 100 111 79 53 68 75 79 100
Working Capital Days 50 40 56 76 61 73 80 82 97
ROCE % 18% 21% 22% 36% 34% 33% 27% 19%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
API Backward Integration (%)
%

Log in to view insights

Please log in to see hidden values.

Login
International Presence (Number of Countries)
Countries
Pipeline Registrations
Dossiers
Total Active International Registrations
Registrations
Number of Prescribers (Cosmeceuticals)
Prescribers
Gross Current Assets (GCA) Days
Days
Major Brands with Revenue > Rs 5 Cr
Brands
Number of SKUs (Dermatology)
SKUs

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 64.90% 64.63%
0.29% 0.32% 0.32% 0.32% 0.90% 1.16% 1.15% 0.90% 0.90% 0.90% 1.14% 1.16%
0.04% 0.02% 0.02% 0.06% 0.12% 0.16% 0.17% 0.17% 0.26% 0.29% 1.90% 2.15%
32.93% 32.93% 32.92% 32.87% 32.25% 31.95% 31.95% 32.20% 32.11% 32.07% 32.07% 32.06%
No. of Shareholders 1,4511,7221,9282,1162,3232,5672,8823,0543,1393,1843,6944,736

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls